China CAR-T Network: 80+ Hospitals, 700+ Trials
Access the world's largest CAR-T therapy ecosystem. China leads globally with 700+ active clinical trials, 80+ NMPA-approved Grade 3A hospitals, and treatment costs of $30K-$80K (70-90% less than USA). Complete coordination for international patients including visa, logistics, and translation.
Why China for CAR-T Therapy?
China has evolved from a peripheral player to a global powerhouse in oncology research.
Global Trial Leader
China accounts for 20-25% of all global oncology trials, up from <5% a decade ago. Leading in novel targets like Claudin18.2 (Gastric) and GPC3 (HCC).
70-90% Cost Savings
Treatment costs $30K-$80K vs $373K-$475K in USA. Savings come from government subsidies, lower manufacturing costs, and competitive pricing among 80+ centers.
30-50% Faster Enrollment
Streamlined ethics approvals and high patient prevalence enable faster trial enrollment, preventing disease progression during waiting periods.
NMPA & ICH-GCP Compliance
Strict regulation by NMPA (China's FDA) with full ICH-GCP compliance. Top hospitals undergo regular unannounced audits by international sponsors.
First-in-Class Innovation
Leading development of dual-target CAR-T, universal CAR-T, armored CAR-T, and solid tumor applications where Western trials have struggled.
International Patient Support
Major hospitals have dedicated international departments with English-speaking coordinators, professional translators, and 24/7 physician liaisons.
Partner Hospitals: Grade 3A Excellence
We exclusively match patients to NMPA-approved Grade 3A public hospitals for trial execution.
Ruijin Hospital
- CAR-T for Leukemia & Lymphoma
- Phase I-III Oncology Trials
- International Patient Department
Peking Union Medical College Hospital
- Comprehensive Oncology Center
- CAR-T & Immunotherapy Trials
- Academic Research Leader
Sun Yat-sen University Cancer Center
- Solid Tumor CAR-T Trials
- Hepatocellular Carcinoma Focus
- International Collaboration
The First Affiliated Hospital of Zhejiang University
- Blood Cancer CAR-T Programs
- Stem Cell Transplant Center
- Multi-Center Trial Network
West China Hospital, Sichuan University
- Comprehensive Cancer Center
- CAR-T & Cellular Therapy
- Western China Hub
Fudan University Shanghai Cancer Center
- Oncology Specialization
- Phase I-III Trials
- International Patient Services
Cost Breakdown: China vs USA
Transparent comparison of treatment costs and total care expenses.
| Cost Component | China (Clinical Trials) | USA (FDA-Approved) | Savings |
|---|---|---|---|
| CAR-T Drug Cost | $30,000 - $80,000 | $373,000 - $475,000 | 70-90% less |
| Hospitalization (2-3 weeks) | $5,000 - $15,000 | $50,000 - $100,000 | 80-90% less |
| Pre-treatment Evaluation | $2,000 - $5,000 | $10,000 - $20,000 | 75-80% less |
| Post-treatment Follow-up (4 weeks) | $3,000 - $8,000 | $20,000 - $40,000 | 80-85% less |
| Total Medical Costs | $40,000 - $108,000 | $453,000 - $635,000 | 75-90% less |
| International Travel (Round-trip) | $1,000 - $3,000 | $500 - $2,000 | Varies by origin |
| Accommodation (4-8 weeks) | $3,000 - $12,000 | $15,000 - $40,000 | 70-80% less |
| Translation Services | Included free | $2,000 - $5,000 | 100% savings |
| Total Cost of Care | $44,000 - $123,000 | $470,500 - $682,000 | 75-90% less |
Logistics & Support for International Patients
Complete coordination from arrival to departure. We handle everything except medical decisions.
Medical Visa Assistance
We provide invitation letters from partner hospitals and guide you through the entire visa application process.
- S1/S2 Medical Visa or L Tourist Visa
- Invitation letter from Grade 3A hospital
- Processing time: 4-7 business days
- Document preparation support
Travel Coordination
Assistance with flight bookings, airport transfers, and local transportation throughout your stay.
- Flight booking assistance
- Airport pickup and drop-off
- Local transportation to hospital
- Emergency travel support
Accommodation
Arrangement of comfortable accommodation near the hospital for you and your companion.
- Hospital-adjacent apartments/hotels
- Short-term and extended stay options
- Companion accommodation
- Kitchen facilities for special diets
Translation Services
Professional medical translators for all consultations, procedures, and documentation.
- English, Arabic, Russian, Turkish
- Medical document translation
- Real-time interpretation during consultations
- Discharge summary translation
Patient Coordinator
Dedicated coordinator available 24/7 throughout your treatment journey in China.
- Single point of contact
- 24/7 availability
- Hospital appointment scheduling
- Emergency assistance
Continuity of Care
Seamless handover back to your home physician with comprehensive English-language documentation.
- English discharge summary
- Long-term monitoring plan
- Direct physician-to-physician communication
- Follow-up coordination
Frequently Asked Questions
Common questions about CAR-T therapy in China for international patients.
Yes. International patients have the legal right to seek medical treatment in China. Our partner hospitals are licensed by NMPA (China's FDA) and many hold JCI accreditation. Treatment is available through both approved products and registered clinical trials.
CAR-T therapy in China typically costs $30,000-$80,000 USD through clinical trials, compared to $373,000-$475,000 for FDA-approved products in the USA. This represents 70-90% cost savings while accessing cutting-edge clinical trials.
International patients typically need a Medical Visa (S1 or S2 visa) or Tourist Visa (L visa) for treatment. We provide invitation letters from partner hospitals and assist with the entire visa application process. Processing time is typically 4-7 business days.
Major Grade 3A hospitals in Beijing, Shanghai, and Guangzhou have international patient departments with English-speaking coordinators. We also provide professional medical translators for all consultations and procedures.
Total stay is typically 4-8 weeks: 1 week for pre-treatment evaluation, 3 days for lymphodepleting chemotherapy, 1 day for CAR-T infusion, 2-3 weeks for inpatient monitoring, and 2-4 weeks for outpatient follow-up before returning home.
Most Chinese CAR-T products are approved by NMPA (China's FDA) for domestic use but not yet FDA-approved for US market. They are available through registered clinical trials with rigorous NMPA oversight and ICH-GCP compliance.
Patient safety is our top priority. All partner hospitals have experienced teams capable of managing CAR-T side effects including CRS and neurotoxicity. We provide 24/7 coordinator support and facilitate direct communication with your home physician if needed.
Yes. We recommend having a companion during treatment. We arrange accommodation for companions and provide translation services for family meetings with the medical team.
Ready to Explore CAR-T Treatment in China?
Submit your case for a free evaluation. Our medical team will assess your eligibility and match you with appropriate trials within 48 hours.
Free coordination • No hidden fees • HIPAA-aligned • 48-hour response